Hims & Hers Health, Inc. HIMS has progressed beyond a direct-to-consumer (DTC) telehealth provider into a broader healthcare ...

Hims & Hers plunged 23% after a major Q1 earnings miss, but long-term growth stays intact via its Novo Nordisk GLP-1 ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

By Sriparna Roy May 21 (Reuters) - Hims & Hers Health said on Thursday it is now offering Canadians with type 2 diabetes a generic version of semaglutide, the active ingredient in Novo Nordisk's ...

Hims & Hers continues growing rapidly, but shrinking margins and rising costs are beginning to test the company's long-term profitability story.

Hims & Hers Health shares fell nearly 4% premarket after the firm proposed a private offering of $300M aggregate principal amount of convertible senior notes due 2032. The interes ...

Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest ...

Hims launched generic Semaglutide in Canada, opening a lower-cost alternative to Novo Nordisk’s Ozempic and Wegovy. ・Health Canada recently approved the first generic semaglutide products in the G7.

Hims & Hers Health will begin selling generic GLP-1 drugs in Canada for 149 Canadian dollars ($108.41) a month. The telehealth company will sell a generic version of Novo Nordisk's Ozempic ...

Feb 10 (Reuters) - Novo Nordisk's U.S. patent lawsuit against Hims & Hers, filed on Monday, ‌marks a new front in the Danish pharmaceutical drugmaker's ‌campaign against companies selling compounded ...

LONDON, Feb 13 (Reuters) - ⁠Hedge ⁠fund bets against Hims & Hers ⁠Health hit their highest in at least a year in January, just before the online telehealth firm clashed with Novo Nordisk over its ...

Hims offers convenient, discreet prescription hair loss treatments for men. Learn if it's right for you and what to expect.